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Summary One hundred and thirty patients with soft tissue sarcoma of the head and neck were treated at the
Royal Marsden Hospital between 1944 and 1988. Pathological review was possible in 103 of these cases; only
pathologically reviewed cases have been analysed. The median age at presentation was 36 years, and 53% were
male. Four had neurofibromatosis type I, and one previous bilateral retinoblastoma. Six had undergone
previous radiotherapy, 12 to 45 years prior to developing sarcoma. The tumours were < 5 cm in 78% of cases
and high grade in 48%. Only one patient presented with lymph node metastases and only one with distant
metastases (to lung). Malignant fibrous histiocytoma was the commonest histological type, occurring in 30
cases.
The overall 5 year survival was 50% (95% CI 39-60). Local tumour was the cause of death in 63% of cases
and 5 year local control was only 47% (95% CI 36-58) with local recurrence occurring as late as 15 years
after treatment. The only favourable independent prognostic factor for survival was the ability to perform
surgery (other than biopsy), with or without radiotherapy, as opposed to radiotherapy alone (hazard ratio
0.39; P = 0.003). Only one patient had a biopsy with no further treatment. Favourable independent prognostic
factors for local control at 5 years were site (tumours of the head as opposed to the neck, hazard ratio 0.42;
P = 0.02) and modality of treatment (combined surgery and radiotherapy compared to either alone, hazard
ratio 0.31; P= 0.002). Patients in the combined modality and single treatment modality groups were well
balanced for T stage, grade and tumour site. The patients in the combined treatment group had less extensive
surgery, yet their local recurrence-free survival was longer.
Unlike soft tissue sarcomas at other sites, those in the head and neck region more often cause death by local
recurrence. The addition of radiotherapy to surgery may result in longer local recurrence-free survival.
Soft tissue sarcomas of the head and neck are rare: they
comprise <1% of head and neck cancers and <10% of all
soft tissue sarcomas (Chang et al., 1991). There have been
few large series and most have included embryonal rhabdo-
myosarcomas which have a different natural history from
other sarcomas and are both radio- and chemosensitive
(Pratt, 1969). We have therefore carried out a retrospective
study of all head and neck sarcomas treated at the Royal
Marsden Hospital (RMH) from 1944-1988. Patients with
embryonal rhabdomyosarcoma and fibromatoses were ex-
cluded. During the long time period involved, histological
classification of these tumours had altered and so all the
cases analysed were subjected to histological review. Prognos-
tic factors for survival and local recurrence were studied. The
implications for a combined surgical and radiotherapeutic
approach to the treatment of these tumours are discussed.
Patients
The medical records of patients referred to the RMH with a
diagnosis of soft tissue sarcoma were reviewed. The head and
neck was defined as any site above the clavicles. Fifty-eight
patients with a diagnosis of embryonal rhabdomyosarcoma
were excluded from this report because of the differences in
clinical behaviour and resonse to treatment of this tumour
type compared with other soft tissue sarcomas. Three
patients with fibromatoses were also excluded because we do
not consider this condition to be sarcomatous. The histo-
logical diagnoses were reviewed by one of us (CF), using
additional staining procedures where appropriate. The histo-
logy review assigned the tumours into three grades (high,
intermediate and low) using the following criteria: synovial
sarcoma, epithelioid sarcoma, alveolar soft part sarcoma and
undifferentiated sarcoma not otherwise specified (NOS) were
always high grade. Well differentiated and myxoid liposar-
coma were always low grade. Other tumour types were scor-
ed according to the extent of necrosis, cellularity, nuclear
pleomorphism and mitotic activity, and graded according to
the total score (Robinson et al., 1992).
The following data were also collected: demographic fac-
tors, tumour stage (UICC), predisposing factors, treatment
details, and local recurrence plus overall survival. Actuarial
plots of survival and local recurrence-free rate, according to
the above facors, were compared using log-rank analysis
(Peto et al., 1977). Multivariate Cox regression analysis was
carried out to determine the independent prognostic factors
for survival and local recurrence (Cox, 1972). Death was not
treated as an event when analysing local recurrence-free rate.
Results
Over 2,500 patients with sarcoma have been treated at the
RMH since 1944. Of these, 130 had soft tissue sarcoma of
the head and neck (with the exclusions mentioned in the
patients' section) which is only 5% of the total. Histological
slides from 103 of these patients were available for review
(Table I) and these patients form the basis of this report. The
patient characteristics are listed in Tables I and II. The
commonest histological diagnosis was malignant fibrous his-
tiocytoma or MFH (30), followed by undifferentiated sar-
coma or NOS (16) and malignant peripheral nerve sheath
tumour or MPNST (16). On review, the histology of 49
patients was changed (Table I). This was particularly com-
mon where the original diagnosis was fibrosarcoma (26 cases)
when the reviewed diagnosis became MFH in eight cases,
NOS in five, synovial sarcoma in four, MPNST in four,
leiomyosarcoma in three and dermatofibrosarcoma pro-
tuberans (DFP) in two. In contrast, the diagnosis of one
patient who had previously been classified as having a
leiomyosarcoma became fibrosarcoma on review.
Predisposing factors to the development of sarcoma were
noted in 11 patients. Four had neurofibromatosis type I, one
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Table I Review of histology
Old New
Fibrosarcoma MFH (8)
NOS (5)
Synovial (4)
MPNST (4)
Leiomyosarcoma (3)
DFP (2)
Spindle cell MPNST (4)
MFH (1)
NOS (1)
Liposarcoma (1)
Leiomyosarcoma MFH (1)
Fibrosarcoma (1)
MFH NOS (2)
DFP (1)
Neurofibrosarcoma MPNST (2)
Schwannoma MPNST (1)
Synovial sarcoma MFH (1)
NOS Leiomyosarcoma (1)
Liposarcoma MPNST (1)
DFP MFH (4)
Epithelioid sarcoma NOS (1)
Patient characteristics
Age 3-84 years (median 36)
Sex 55 male (53%)
48 female (47%)
Reviewed histology Low grade 23 (22%)
Intermediate 31 (30%)
High 49 (48%)
MFH 30
NOS 16
MPNST 16
Leiomyosarcoma 9
Fibrosarcoma 8
Synovial sarcoma 7
Liposarcoma 5
DFP 4
Angiosarcoma 3
Alveolar soft part 2
Pleomorphic rhabdomyosarcoma 2
Ewings of soft tissue I
Table II Stage at presentation
Stage at presentation Number
IA (GI, TI) 17
IB (GI, T2) 6
IIA (G2, TI) 24
IIB (G2, T2) 7
IIIA (G3, TI) 38
IIIB (G3, T2) 9
IVA (positive nodes) 1
IVB (metastasis) I
Totals: Ti 80 (78%)
T2 23 (22%)
NO 102 (99%)
Ni 1 (1%) (leiomyosarcoma)
MO 102 (99%)
MI 1 (1%) (lung metastases)
bilateral retinoblastoma and six had received previous irra-
diation to the head or neck region between 12 and 45 years
before the development of sarcoma which was within the
radiation field. The indications for radiotherapy were cervical
Hodgkins disease (two patients), carcinoma of the breast
(one patient), scalp tinea (one patient), a partoid pleomor-
phic adenoma (one patient) and unknown in one patient. All
post radiation sarcomas were MFH.
Staging
Twenty-three tumours were low grade, 31 intermediate and
49 high grade. Patients were staged using the 1987 UICC
system. The majority of patients (38) had stage IIIA tumours
(Table II).
Surgery
Surgery was carried out in 79 of the 103 patients. The
surgical procedures were defined as: wide excision where at
least a I cm margin of histological clearance was achieved
around the tumour, complete excision where up to 9 mm of
clearance was achieved and partial excision where the resec-
tion was incomplete. In the remaining 24 patients (23%),
biopsy only was performed; 23 of these then received radio-
therapy as part of their treatment. Elective nodal dissection
was not performed. The type of initial surgery was wide in 14
patients (14%), complete in 48 (47%) and partial in 17
(16%).
Radiotherapy
Radiotherapy was given to 58 patients. It was the sole treat-
ment modality in 17 (17%) who had inoperable tumours.
The doses used varied from 12-76 Gy (median 55 Gy).
Treatment was given pre-operatively in four cases and post-
operatively in 31. The majority (28 cases) received fraction
sizes <2.2 Gy treating daily to a total dose of > 55 Gy.
Twenty-one of these had between 55-66 Gy total dose, six
received hypofractionated treatment (6.6 Gy per week) and
one had a hyperfractionated regime of 1.25 Gy b.d. to
75.6 Gy in 6 weeks. Lymph nodes were not electively treated.
As in extremity sarcomas (Robinson et al., 1990), treatment
was given in two phases, with shrinking fields.
Chemotherapy
Fifteen patients were given chemotherapy. One patient
received chemotherapy alone, one after surgery, six after
radiotherapy, and seven after both surgery and radiotherapy.
Seven patients were given combination chemotherapy. The
chemotherapy regimens included methotrexate (nine patients),
doxorubicin (seven), vincristine (six), ifosfamide (four) or
cyclophosphamide (five).
Survival
The median follow-up was 50 months (range 1-305). Forty-
eight patients have died, 46 from sarcoma (Table III). Local
disease was the sole cause of death in 30 (65% of sarcoma
deaths), and metastases in 16 (35% of sarcoma deaths).
There were no treatment related deaths. Overall actuarial S
year survival was 50%. Figure 1 compares the survival of
these patients with that of patients with soft tissue sarcoma
at all other sites treated at the same institution between
1970-1990 (Robinson, personal communication, 1992). The
survival of patients with head and neck sarcoma is signi-
ficantly worse than that seen with such sarcomas at extremity
and truncal sites, but is better than for those arising in the
retroperitoneum. Five year survival of the 103 patient ac-
cording to age, site, histology, grade, T stage and treatment
are detailed in Table V. The only significant associations
with 5 year survival on univariate analysis were age (patients
<30 did better than older patients, P<0.05) and treatment
(those treated with radiotherapy alone did worse than those
treated with surgery ± radiotherapy, P<0.01 Figure 2).
Tumour site, histology, T stage and grade did not have any
impact on survival in this series.
There were comparatively few events in this study, thus
only large differences in prognosis could reliably be detected.
For example, with 48 deaths, it would be possible only to
reliably detect differences corresponding to a 60% 5 year
survival in one group compared with a 30% 5 year survival
in another group (P<0.01; 90% power).
The median survival of the patients with neurofibromatosisHEAD AND NECK SARCOMAS 203
100
90
> 80
-
70-
60 60
.0
2 30-
20-
10 -
0
0 1 2 3 4 5 6 7 8 9 1011121314151617181920
Years since primary diagnosis
Figure 1 Overall survival by site of sarcoma. Head and neck site
(-) vs other sites (---). 95% CI bars are shown. P<0.05.
Table III Cause of death
Cause of Grade
death Low Intermediate High Total
Local disease 13 10 7 30 (63%)
Metastases 6 8 2 16 (33%)
Other 0 1 1 2 (4%)
was 52 months which was not significantly different from the
group as a whole, but those with radiation induced sarcoma
had a poorer median survival of 7 months.
Metastasis
Twenty-nine patients have developed metastases, most com-
monly in the lung (20 cases: 69%). These were the cause of
death in 16 patients (33% of all deaths). Other sites of
metastasis were liver, bone, brain and skin. Overall actuarial
metastasis free-survival was 68% at 5 years and 56% at 10
years. Five year metastasis free-survival according to age,
histology, site, size, grade and treatment are detailed in Table
V. No significant factors for the development of metastasis
were seen on univariate analysis, probably due to the small
number of events that occurred.
Radiation morbidity
Only two patients have developed radionecrosis, both were of
soft tissue and followed hypofractionated radiotherapy. One
had 46.2 Gy in 7 weekly fractions and the other 39 Gy in 5
weekly fractions. Radionecrosis appeared 88 and 14 months
respectively after treatment. This was part of a hypofrac-
tionation study which has since been concluded (Ashby et al.,
1986).
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Figure 2 Five year survival by treatment modality. Surgery (---)
vs radiotherapy and surgery (-), vs radiotherapy alone (---- lower
curve), P<0.01.
Table IV Initial treatment
Initial treatment Site
(no.) % total Neck Antrum Parotid Cheek Othera
S (43) 42% 12 3 4 4 20
RT(17) 17% 4 4 2 7
C (1) 1% 1
S+RT (24) 23% 7 2 1 14
RT-S (4) 4% 1 1 2
S-C (1) 1% 1
RT+C (6) 6% 1 5
S-*RT-*C (7) 7% 1 1 5
Total 24 (23%) 10 8 6 55
S = surgery; RT = radiotherapy; C = chemotherapy. 'Other sites in
detail.
Initial treatment Site (number ofpatients)
S Soft palate
Thyroid
Alveolus
Nose
Nasopharynx
Pinna
Skin of forehead
Temple
Occiput
Scalp
Tongue
Lacrimal gland
Ethmoid
RT Larynx
Nasopharynx
Orbit
Middle ear
Ethmoid
C Tonsil
S-*RT Thyroid
Alveolus
Nose
Nasopharynx
Orbit
Conjuctiva
Chin
Temple
Scalp
Tongue
Tonsil
RT+S Orbit
Tonsil
S->C Orbit
RT->C Cervical oesophagus
Jaw
Larynx
Orbit
Temple
S+RT+C Larynx
Thyroid
Orbit
Occiput
Ethmoid
(2)
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
Local recurrence
Fifty patients have developed local recurrence. This was the
cause of death in 30 (63% of all deaths). Overall actuarial 5
year local recurrence-free rate was only 47% (Figure 3).
Local recurrence occurred as late as 15 years after diagnosis.
Head and neck sarcomas have a higher local recurrence rate
than at all other sites except for retroperitoneum. Five year
local recurrence free rate according to age, site, T stage,
histology, grade and treatment are detailed in Table V. Only
age and treatment were conventionally significant factors
(P<0.05) on univariate analysis. Local recurrence was less
common in younger patients and in those treated with a
combination of surgery and radiotherapy. Local recurrence
predated metastasis in 12 cases, occurred simultaneously in
seven, but did not postdate metastases in any case. After
local recurrence, the median survival was 3.3 years and the 5
year survival was 28%. The median time to a further local
recurrence after one local recurrence was 1.9 years. There204 R.A. EELES et al.
Table V Univariate analysis
Number S year 5 year LR-free Metastasis
survival survival free-survival
Age
<30 36 62 (42-77) 68 (46-82) 82 (61-92)
30-50 35 45 (26-63) 43 (25-60) 54 (33-71)
>50 32 40 (21-58) 30 (11-51) 63 (38-80)
P<0.05 P<0.01 n.s.
Site
Neck 24 45 (21-67) 39 (19-58) 60 (34-79)
Head 79 51 (38-63) 50 (36-63) 69 (55-79)
n.s. (P = 0.06) n.s.
Tstage
TI 80 52 (39-64) 47 (34-59) 64 (51-75)
T2 23 43 (21-63) 49 (24-70) 75 (45-90)
n.s. n.s. n.s.
Histology
MFH 30 46 (26-64) 43 (25-60) 63 (42-78)
Other 73 51 (37-63) 50 (35-64) 69 (53-80)
n.s. n.s. n.s.
Grade
High 49 54 (37-68) 57 (39-72) 68 (50-81)
Int. 31 37 (18-55) 30(13-50) 54(31-72)
Low 23 59 (33-78) 50 (25-70) 79 (47-93)
n.s. n.s. n.s.
Treatment
RT + S 35 55 (35-71) 60 (36-77) 60 (36-76)
S 43 61 (42-76) 40 (24-54) 70 (50-83)
RT 17 21 (6-42) 36 (12-61) 72 (38-89)
P<0.01 P<0.05 n.s.
LR = local recurrence; Int. = intermediate grade; n.s. = non-
significant.
was no difference in the time to second local recurrence
between different treatment modalities (but numbers are
small).
Treatment oflocal recurrence
Fifty patients experienced a local recurrence, of whom 44
received further treatment. Surgery was performed in 29
comprising wide resection in four (14%), complete resection
in 19 (66%), and partial resection only in six (20%). It was
the sole treatment modality for 17 patients (one wide resec-
tion, 15 complete and one partial): six of these patients
treated with surgery alone have relapsed locally (35%).
Radiotherapy was given for local recurrence in 19 cases
and was the sole treatment modality in ten (20% of local
recurrences). Eleven (58%) of the local recurrence group
treated with radiotherapy have died of disease, eight from
further local recurrence and three from metastases. Six of the
patients treated with radiotherapy alone (60%) have died,
three from local disease, two from metastasis and one from
intercurrent disease.
Surgery and radiotherapy were used together in ten
patients who had a local recurrence (the resection was wide
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in three, complete in three and partial in four). Of these ten,
five have died of local disease, one has died ofmetastasis and
four are alive without disease.
Chemotherapy was given to 13 patients as part of treat-
ment of local recurrence; in three it was the sole treatment.
Eight of the 13 have died, and in all cases death was from
local disease.
Treatment ofmetastasis
Twenty-nine patients developed metastatic disease after pre-
sentation. Twelve had no treatment. The remainder had
treatment involving surgery in five, radiotherapy in four and
chemotherapy in eight. Chemotherapy achieved a complete
response in one patient and a partial response in another.
Multivariate analysis
Multivariate analysis using the Cox model was performed to
determine the significant prognostic factors for survival, fai-
lure of local control and disease free survival for the full
follow-up period, and at 5 years. Analyses were done for
these two time periods because of the protracted follow-up.
The results of these analyses are shown in Table VI. The only
independent prognostic factor for survival (at both follow-up
times) was the use of surgery vs biospy only (hazard ratio
0.39). T stage and grade as prognostic factors did not reach
statistical significance. Multivariate analysis for overall
disease-free survival only showed age to be a prognostic
factor (P = 0.001).
The independent prognostic factors for local recurrence at
5 years were site (Figure 4) and treatment modality (Figure
5). At 5 years, tumours of the head had a better local
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Figure 4 Five year LR - free rate by site. Head (---) vs neck
(-), P=0.06.
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Figure 3 Local recurrence (LR) free rate in head and neck
sarcoma patients.
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Figure 5 Five year LR - free rate by treatment. Surgery and
radiotherapy (-) vs radiotherapy (---) vs Surgery (---),
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Table VI Multivariate analysis
Hazard ratio (95% CI)
Endpoint Overall 5 Year
Survival Surgery(S) Surgery(S)
Biopsy only 1.00 Biopsy only 1.00
Surgery 0.39 (0.22-0.70) Surgery 0.37 (0.20-0.69)
P=0.003 P<0.01
Local recurrence Radiotherapy (RT) RT& S
None 1.00 Single modality 1.00
RT 0.38 (0.21-0.69) Both 0.31 (0.13-0.71)
P= 0.001 P= 0.002
Age Site
K 30 1.00 Neck 1.00
31-50 1.82 (1.27-2.63) Head 0.42 (0.21-0.83)
50+ 3.32 (2.32-4.81) P = 0.02
P=0.001
Histology
Other 1.00
MFH 1.92 (1.06-3.48)
P= 0.035
Disease-free survival Age Age
<30 1.00 <30 1.00
31-50 1.69 (1.24-2.31) 31-50 1.48 (1.05-2.07)
50+ 2.87 (2.10-3.92) 50+ 2.18 (1.56-3.06)
P=0.001 P=0.02
recurrence free survival than those of the neck (hazard ratio
0.42; P = 0.02). Patients receiving a combination of surgery
and radiotherapy had a longer recurrence free survival than
those receiving surgery or radiotherapy alone (hazard ratio
0.31; P = 0.002). The single and combined modality groups
were well balanced with regard to T stage, grade and tumour
site; the combined modality group, which had a better local
recurrence free survival, had a lower percentage of patients
who had undergone complete or wide surgery. At 15 years,
the use of radiotherapy remained an independent prognostic
factor (P = 0.001); age (P = 0.001) and histology (P = 0.035)
also became independent prognostic factors.
Discussion
Soft tissue sarcomas of the head and neck are uncommon
and there is only a small number of reported series (Farr et
al., 1981; Littman et al., 1983; Wharam et al., 1984; Greager
et al., 1985; 1986; Fromm et al., 1986; Harmer et al., 1986;
Weber et al., 1986; Tsujimoto et al., 1988; Figueiredo et al.,
1988; Freedman et al., 1989; Mandard et al., 1989; Rao et
al., 1989; Ruka et al., 1989; Frankenthaler et al., 1990).
These are summarised in Table VII.
When assessing such a series, two potential problems arise.
The first is that inclusion of embryonal rhabdomyosarcomas
and primary bone sarcomas confuses the overall picture
because they have different clinical behaviour. Embryonal
rhabdomyosarcomas are very chemosensitive, unlike other
soft tissue sarcomas. Fibromatoses should also be excluded
because although they may recur locally, they have no meta-
static potential and are not regarded as true sarcomas (En-
zinger & Weiss, 1988).
The second point to consider is the change in histological
classification that has occurred over the last 50 years
(Frankenthaler et al., 1990). In the past, carcinomas with an
extensive desmoplastic reaction were sometimes reported as
fibrosarcomas. True fibrosarcomas are now thought to be
rare (Fisher, 1990). Many sarcomas previously classified as
fibrosarcoma have been reclassified as malignant fibrous his-
tiocytoma, synovial sarcoma or MPNST following the deve-
lopment of immunohistochemistry and electron microscopy.
This was the case in this series.
There are also differences between the American and
British literature in what is included under the classification
of soft tissue sarcoma: for example, the American classi-
fication would include neuroblastoma and paraganglioma
(Farr, 1981; Chang et al., 1991) which in the UK would not
be regarded as soft tissue sarcoma. Our series has therefore
Table VII Summary of previous series
Number Histology 5 year 5 year
Reference ofpatients review survival LR-free
Farr, 1981 285 ?no 32%
(I19)
Figueiredo et al. (1988) 94 yes 39%
(79)
Frankenthaler et al. (1990) 118 yes
(86)
Freedman et al. (1989) 352 yes 67%
(216)
Fromm et al. (1986) 20
(5)
Greager et al. (1986) 53 ?no - 54%
(46)
Littman et al. (1983) 32 yes 75%
(9)
Mandard et al. (1989) 109 yes
(109)
Rao et al. (1989) 121 yes - -
(17)
Ruka et al. (1989) 21 yes - -
(?)
Tsujimoto et al. (1988) 43 yes - -
(40)
Weber et al. (1986) 188 yes
(155)
Wharam et al. (1984) 72 yes 78%
(27)
Numbers refer to patient with head and neck sarcoma and those in
parentheses are the numbers in each series after applying the same
exclusions as in our series. Prognostic factors are for survival unless
stated (LR = local recurrence).
excluded embryonal rhabdomyosarcoma, neuroblastoma, bone
sarcomas and fibromatoses, unlike most of the previously
reported series. All tumours analysed in our study had cur-
rent histological review.
For limb sarcomas, resection is usually defined using the
Enneking classification (Simon & Enneking, 1976) which is
inappropriate for head and neck tumours because of the
difference in anatomical setting. As with sarcomas at other
sites, surgical excision of tumours in the head and neck
region remains the definitive treatment modality. The extent
and adequacy of excision will largely determine survival and
the incidence of local recurrence (Enneking, 1983). Extracap-
sular enucleation of the tumour will result in up to a 90%
local recurrence rate because of the presence of microscopic
pseudopodia which tend to grow through the pseudocapsule
into the surrounding tissue, and also the presence of 'skip206 R.A. EELES et al.
lesions' some distance from the main tumour mass. Wider
excision, usually defined in the limb as 5 cm outside the
capsule, is associated with a better prognosis, but ideally
'compartmentectomy' should be attempted which results in
only a 21% risk of local recurrence. In the head and neck
region, however, wide excision is rarely possible because at
presentation, the majority of tumours have extended beyond
the confines of their local origin and many lie in close
proximity to vital neurovascular structures which cannot be
resected safely without risk of severe morbidity. Compart-
mentectomy has no meaning in the head and neck, and the
extent of surgical resection has therefore been redefined as
listed in the results so as to be more appropriate to this site.
The overall survival of sarcoma of the head and neck is
shorter than that of limb sarcomas which have a 70% 5 year
survival (Robinson et al., 1990) and death is more often due
to local recurrence. The 5 year local recurrence free survival
(47%) is also inferior to that for limb sarcomas. Local
recurrence can occur late, even as late as 15 years after
treatment. Improvement in local control is therefore of para-
mount importance in treating sarcomas occurring in the head
and neck site.
Although numbers are small, local recurrence either pre-
dated or was simultaneous with metastasis. In limb soft tissue
sarcomas local recurrence is associated with the development
of metastases (Stotter et al., 1990).
Univariate analysis at 5 years has shown that younger age
at diagnosis, and operability are significant prognostic factors
for survival. The group treated by radiotherapy alone were
inoperable and therefore had a very poor survival (21% at 5
years). Operability is the only significant prognostic variable
for survival in the multivariate analysis (P = 0.003).
Multivariate analysis for local control showed that
tumours in the neck had a lower local recurrence free sur-
vival at 5 (but not at 15) years; P = 0.02. This is not caused
by interactions with other factors such as tumour size. Some
series suggest the opposite, namely that better local control
can be obtained for tumours in the neck (Greager et al.,
1985). Wharam et al. (1984) found that tumours of the neck
had a higher risk of local recurrence, although their series
consisted predominantly of embryonal rhabdomyosarcoma
which was excluded from our series.
Multivariate analysis for local recurrence has shown that
at 5 years the use of combined modality treatment (radio-
therapy and surgery) is superior to either alone (P = 0.002).
This is despite the fact that the combined modality group
had less extensive surgery. Obviously this is not a randomised
sample, but it would be very difficult to perform a random-
ised study of combined vs a single modality treatment in such
a rare tumour type. The addition of radiotherapy remains an
independent prognostic factor for local recurrence-free sur-
vival for the length of study follow-up, beyond 5 years
(P = 0.001).
In the management of any individual, the risk of local
recurrence would have to be weighed against the long term
morbidity of giving radiotherapy, especially if the patient
were young, the tumour was low grade, and there had been a
wide resection according to our criteria. In this series how-
ever, wide resection was only possible in 14% of cases. In
many patients such clearance is not possible and we would
therefore recommend the use of adjuvant radiotherapy for
the majority. The majority of our patients received 55-66 Gy
using daily fractions of <2.2 Gy. Within this dose range it
would not be possible to show a dose response because of the
small numbers involved.
Combined modality treatment with radiotherapy and sur-
gery achieves a higher local recurrence-free survival, although
not an improvement in overall survival. However, in the
management of head and neck sarcoma, where morbidity
and often death result from local recurrence, local control is
of paramount importance. This combined approach to treat-
ment should always be considered when managing soft tissue
sarcomas at this site where it is vital to obtain local control.
We should like to thank Mr M. Frampton, Consultant Surgeon at
Bedford General Hospital for his help, Mrs D. Eagle for tracing the
histological slides, and Miss C. Evans for help with typing the
manuscript.
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